EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer

H. Yamaguchi, Y. Du, K. Nakai, M. Ding, S. S. Chang, J. L. Hsu, J. Yao, Y. Wei, L. Nie, S. Jiao, W. C. Chang, C. H. Chen, Y. Yu, G. N. Hortobagyi, M. C. Hung

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

Inhibitors against poly (ADP-ribose) polymerase (PARP) are promising targeted agents currently used to treat BRCA-mutant ovarian cancer and are in clinical trials for other cancer types, including BRCA-mutant breast cancer. To enhance the clinical response to PARP inhibitors (PARPis), understanding the mechanisms underlying PARPi sensitivity is urgently needed. Here, we show enhancer of zeste homolog 2 (EZH2), an enzyme that catalyzes H3 lysine trimethylation and associates with oncogenic function, contributes to PARPi sensitivity in breast cancer cells. Mechanistically, upon oxidative stress or alkylating DNA damage, PARP1 interacts with and attaches poly-ADP-ribose (PAR) chains to EZH2. PARylation of EZH2 by PARP1 then induces PRC2 complex dissociation and EZH2 downregulation, which in turn reduces EZH2-mediated H3 trimethylation. In contrast, inhibition of PARP by PARPi attenuates alkylating DNA damage-induced EZH2 downregulation, thereby promoting EZH2-mediated gene silencing and cancer stem cell property compared with PARPi-untreated cells. Moreover, the addition of an EZH2 inhibitor sensitizes the BRCA-mutant breast cells to PARPi. Thus, these results may provide a rationale for combining PARP and EZH2 inhibition as a therapeutic strategy for BRCA-mutated breast and ovarian cancers.

Original languageEnglish (US)
Pages (from-to)208-217
Number of pages10
JournalOncogene
Volume37
Issue number2
DOIs
StatePublished - Jan 11 2018

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Fingerprint Dive into the research topics of 'EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Yamaguchi, H., Du, Y., Nakai, K., Ding, M., Chang, S. S., Hsu, J. L., Yao, J., Wei, Y., Nie, L., Jiao, S., Chang, W. C., Chen, C. H., Yu, Y., Hortobagyi, G. N., & Hung, M. C. (2018). EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer. Oncogene, 37(2), 208-217. https://doi.org/10.1038/onc.2017.311